Netscientific Share Discussion Threads

[investordave] 13/2/2023 14:38

Here we go again... the weekly shop sellers have arrived.

[kingston78] 13/2/2023 11:50

The share price will at least double this year from this level. This is a bargain share that investors have previously ignored. A number of institutional investors subscribed for placing shares at 130 p previously.

The share chart is strong and powerful with an upward movement. It faltered last time but I believe that it will sustain this time.

[vikeshm1] 13/2/2023 11:44

I read the chronicle it was tipped on friday. Because of that will the share fall first after this big rise or it it worth buying in despite?

[blakieboy7] 13/2/2023 10:23

Any day now! Bloody phone

[blakieboy7] 13/2/2023 10:16

Last quarterly update was 14th November, news due at day nowadays

[kingston78] 13/2/2023 08:46

History always repeats itself. One day the share price will go up to 180 p. Please look at the share chart.

[blakieboy7] 13/2/2023 08:46

Agreed Sent. Quarterly update is due very shortly, hopefully we'll get some positive updates

[senttothegallows] 13/2/2023 08:43

Still way less than 50% of NAV absolute steel down here still imho

[blakieboy7] 13/2/2023 08:30

Nice start to the week

[investordave] 10/2/2023 18:31

Long may it continue.

[blakieboy7] 10/2/2023 17:44

Imagine the share price when PDSB moves!!

[loafofbread] 10/2/2023 17:33

Have to say that is a pretty good day!

[mirabeau] 10/2/2023 08:26

It's free access to ST IC column if u go through Google search

[blakieboy7] 10/2/2023 08:17

This rerating is long overdue anyway

[wapper] 10/2/2023 08:14

Looking good today

[blakieboy7] 09/2/2023 21:22

It's a shame it's subscription only

[loafofbread] 09/2/2023 20:19

As I posted last night. An odd move with no news.....

Now we know why...


Simon T has just announced (after market closed) his 8 shares to make the 2023 bargain shares portfolio which includes NSCI. Expect more upward movement tomorrow on the back of the article.

GLA

[blakieboy7] 09/2/2023 14:01

PDSB up 6% pre market

[blakieboy7] 09/2/2023 13:08

Found another useful PDSB info link htTps://biotickr.com/biotech-investment-blog/quicktake-pds-biotech-pdsb

[loafofbread] 09/2/2023 10:35

Post close last night.

A cure for flu?

08/02/2023 9:00pm
GlobeNewswire Inc.

PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that preclinical studies involving Infectimune™, PDS Biotech’s novel investigational immune activating platform, were published in the peer-reviewed journal, Viruses, demonstrating the technology’s ability to generate a broad immune response against viruses, including SARS-CoV-2 and multiple strains of influenza.
The paper, titled, “Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice,” highlighted results from preclinical studies. It was found that Infectimune™ (R-DOTAP) promoted strong T cell and antibody immune responses in both single- and multi-viral antigen (protein) containing vaccines. The vaccines induced antigen-specific and multi-cytokine-inducing CD8 and CD4 T cells associated with antigen-specific killing and immune memory, respectively.

Infectimune™ was tested in separate animal models of SARS-CoV-2 and influenza. Data suggest that Infectimune™ promotes robust neutralizing antibody and T cell responses to all three recombinant SARS‐CoV-2 spike protein variants tested in the studies. The investigational universal flu vaccine, containing two computationally optimized broadly reactive antigen (COBRA) influenza proteins, demonstrated induction of T cell and neutralizing antibodies against multiple strains of influenza. Robust T cell responses were also generated to influenza nucleoprotein, a protein contained in non-mutating regions of the virus. Importantly, these Infectimune™ induced neutralizing antibody and T cell responses completely protected animals from lethal challenges with live SARS-CoV-2 and influenza viruses. The Infectimune™ based vaccines also facilitated significant dose sparing of the viral protein antigens.

“We are encouraged by the data reported in Viruses which suggest that Infectimune™ is a promising platform for the effective delivery of recombinant protein antigens to the immune system and activation of the immune system for the development of next‐generation universal vaccines against respiratory viruses, including influenza and SARS-CoV-2,” stated Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech and one of the co-authors of the study. “PDS Biotech is advancing our Infectimune™ based programs, and these studies highlight the potential of Infectimune™ to induce memory T cell responses against viral antigens that can provide the immune system with long-term memory and sustained protection against infectious pathogens over an extended period of time.”

The research was funded in part by the National Institute of Allergy and Infectious Diseases, the University of Kentucky Flow Cytometry & Immune Monitoring and PDS Biotech.

About Infectimune™

Infectimune™ is a novel investigational immune activating platform that generates broad and robust antibody and T cell responses that provide durable protection against infectious disease. Infectimune™ based vaccines are given by intramuscular injection and generate robust and durable protection against infectious agents in preclinical studies. Infectimune™ based vaccines have demonstrated safety in preclinical studies and appear to provide more robust and longer-lasting protection against infectious disease.

About PDS Biotechnology

[blakieboy7] 08/2/2023 19:10

Loaf the quarterly results are due next week or so

[loafofbread] 08/2/2023 18:50

Can't see any reason for today's buying so lets hope there is some news on the way.

[blakieboy7] 03/2/2023 11:45

The next quarterly update isn't far off now, a week or so

[longterm3] 02/2/2023 14:46

I think that only the first 6,400 trade was a sell.